8-K: Nurix Therapeutics 2026 Annual Meeting Results

Nurix Therapeutics stockholders re-elected three directors and ratified the appointment of its independent auditor.

Summary

• The 2026 Annual Meeting of Stockholders was held on May 15, 2026, via live webcast.
• A quorum was achieved with 83,747,013 shares present, representing 80.98% of voting power.
• Stockholders elected Arthur T. Sands, M.D., Ph.D., Roger Dansey, M.D., and Paul M. Silva as Class III directors for three-year terms.
• PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
• Executive compensation was approved on a non-binding advisory basis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the filing reports standard corporate housekeeping and routine annual meeting outcomes.

Positives

• High voter turnout with 80.98% of shares represented, indicating strong shareholder engagement.
• Strong support for the board's recommended director nominees.
• Overwhelming approval for the ratification of the independent auditor.
• Successful advisory approval of executive compensation packages.

Negatives

• Significant 'withheld' votes for directors Arthur T. Sands (16,334,570) and Paul M. Silva (20,628,906) relative to total votes cast.

Risks

• Potential for future shareholder dissatisfaction regarding board composition given the notable number of withheld votes for specific directors.

Future Outlook

The company continues its operations under the oversight of the re-elected board and maintains its current accounting firm for the 2026 fiscal year.

Industry Context

StockSavvy.ai notes that routine annual meeting results for clinical-stage biotech firms like Nurix typically reflect stable governance, though the high withheld vote count for specific directors warrants monitoring for potential activist interest or governance concerns.

Comparison to Industry Standards

• The ratification of auditors is standard practice for Nasdaq-listed companies.
• The advisory vote on executive compensation is a standard requirement under the Dodd-Frank Act for public companies.
• Director election results are consistent with typical outcomes for mid-cap biotechnology firms.

Corporate Governance

Stakeholder Impact

• Shareholders maintain continuity in board leadership.
• Company maintains established financial oversight through the retention of PricewaterhouseCoopers LLP.

Next Steps

• Directors will serve three-year terms expiring at the 2029 annual meeting.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Annual Meeting, Proxy Voting, Corporate Governance, Biotech